Tactile Systems Technology (NASDAQ:TCMD) Stock Rating Lowered by B. Riley

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) was downgraded by equities researchers at B. Riley from a "buy" rating to a "neutral" rating in a research note issued on Wednesday, Marketbeat reports. They currently have a $18.00 price objective on the stock, down from their prior price objective of $23.00. B. Riley's price target suggests a potential upside of 19.60% from the company's previous close. B. Riley also issued estimates for Tactile Systems Technology's Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.44 EPS, FY2025 earnings at $0.75 EPS and FY2026 earnings at $0.81 EPS.

Other research analysts have also recently issued reports about the company. BTIG Research cut Tactile Systems Technology from a "buy" rating to a "neutral" rating in a report on Tuesday, November 5th. Oppenheimer lowered shares of Tactile Systems Technology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. Finally, StockNews.com lowered shares of Tactile Systems Technology from a "strong-buy" rating to a "buy" rating in a research report on Thursday, January 16th.

Tactile Systems Technology Price Performance

Shares of NASDAQ:TCMD traded down $0.33 during trading on Wednesday, reaching $15.05. 578,279 shares of the company's stock traded hands, compared to its average volume of 330,612. The company has a quick ratio of 3.80, a current ratio of 4.36 and a debt-to-equity ratio of 0.11. Tactile Systems Technology has a fifty-two week low of $11.12 and a fifty-two week high of $21.10. The firm has a market cap of $354.88 million, a PE ratio of 21.50 and a beta of 1.20. The company has a 50-day simple moving average of $17.26 and a 200-day simple moving average of $15.69.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.09. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. The company had revenue of $85.59 million for the quarter, compared to analysts' expectations of $85.39 million. As a group, analysts predict that Tactile Systems Technology will post 0.7 earnings per share for the current year.

Institutional Trading of Tactile Systems Technology

Institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of Tactile Systems Technology by 28.1% during the 3rd quarter. FMR LLC now owns 79,348 shares of the company's stock valued at $1,159,000 after buying an additional 17,393 shares during the period. Wasatch Advisors LP raised its position in Tactile Systems Technology by 9.8% in the third quarter. Wasatch Advisors LP now owns 727,194 shares of the company's stock valued at $10,624,000 after purchasing an additional 64,684 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Tactile Systems Technology in the fourth quarter valued at approximately $1,328,000. Geode Capital Management LLC raised its position in Tactile Systems Technology by 1.5% in the third quarter. Geode Capital Management LLC now owns 558,667 shares of the company's stock valued at $8,164,000 after purchasing an additional 8,422 shares during the period. Finally, BNP Paribas Financial Markets raised its position in Tactile Systems Technology by 16.4% in the third quarter. BNP Paribas Financial Markets now owns 45,374 shares of the company's stock valued at $663,000 after purchasing an additional 6,401 shares during the period. Hedge funds and other institutional investors own 83.43% of the company's stock.

About Tactile Systems Technology

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.